Becton, Dickinson and Company $BDX Shares Sold by Lazard Freres Gestion S.A.S.

02 Jan 2026, 12:06 by Kim Johansen · The Markets Daily

Lazard Freres Gestion S.A.S. trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 10.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 461,790 shares of the medical instruments supplier’s stock after selling 52,323 shares during the period. Becton, Dickinson and Company accounts for 1.6% of Lazard Freres Gestion S.A.S.’s portfolio, making the stock its 18th biggest position. Lazard Freres Gestion S.A.S. owned approximately 0.16% of Becton, Dickinson and Company worth $86,433,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Becton, Dickinson and Company by 15.4% during the second quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock worth $5,565,182,000 after acquiring an additional 4,305,947 shares during the period. First Eagle Investment Management LLC boosted its stake in Becton, Dickinson and Company by 59.2% in the second quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock valued at $1,513,421,000 after acquiring an additional 3,268,478 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in shares of Becton, Dickinson and Company by 24.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 8,514,446 shares of the medical instruments supplier’s stock valued at $1,466,613,000 after purchasing an additional 1,670,590 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Becton, Dickinson and Company by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 6,723,702 shares of the medical instruments supplier’s stock worth $1,153,157,000 after purchasing an additional 244,199 shares during the period. Finally, Norges Bank acquired a new stake in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $653,377,000. 86.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the sale, the director directly owned 35,816 shares in the company, valued at $6,324,389.28. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael David Garrison sold 629 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total value of $123,302.87. Following the transaction, the executive vice president owned 13,105 shares in the company, valued at approximately $2,568,973.15. This trade represents a 4.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,052 shares of company stock valued at $201,235 over the last 90 days. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $194.11 on Friday. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $251.99. The stock’s fifty day moving average is $190.85 and its 200-day moving average is $186.79. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. The firm has a market capitalization of $55.30 billion, a price-to-earnings ratio of 33.30, a price-to-earnings-growth ratio of 1.79 and a beta of 0.23.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were issued a dividend of $1.05 per share. The ex-dividend date of this dividend was Monday, December 8th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is presently 72.04%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Jefferies Financial Group boosted their price objective on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Morgan Stanley raised their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Piper Sandler lowered their price target on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research report on Friday, November 7th. Royal Bank Of Canada increased their price objective on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 17th. Finally, Stifel Nicolaus reduced their target price on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a research note on Friday, November 7th. Four research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $205.64.

Get Our Latest Analysis on BDX

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.